Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

Overview of attention for article published in BMC Neurology, May 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 32 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

galcanezumab

Cited by Canadian Agency for Drugs and Technologies in Health on 28 Feb 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.